How to Get Dayvigo (Lemborexant) in Alabama

What Is Dayvigo and Why Does It Require Special Access Steps?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for the treatment of insomnia in adults characterized by difficulty with sleep onset and/or sleep maintenance [1]. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking wake-promoting orexin neuropeptides rather than broadly depressing the central nervous system.

Because the DEA classifies lemborexant as a Schedule IV controlled substance, prescribers must hold an active DEA registration and comply with Alabama Board of Medical Examiners rules for controlled substance prescribing [2]. Alabama permits telehealth prescribing of Schedule IV medications, but the prescriber must be licensed in the state or hold an Alabama telemedicine license. This regulatory layer is the primary reason access requires more than a simple refill request. In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly improved latency to persistent sleep compared with placebo at one month (p<0.001 for both doses) [3].

Step 1: Get a Prescription from an Alabama-Licensed Provider

The fastest route to a Dayvigo prescription in Alabama is a visit (in-person or telehealth) with a physician, nurse practitioner, or physician assistant licensed in the state. All three provider types can prescribe Schedule IV controlled substances in Alabama, though NPs must maintain a collaborative practice agreement with a supervising physician under Alabama Board of Nursing rules [4].

During the visit, your provider will evaluate your insomnia history, rule out obstructive sleep apnea or other secondary causes, and review your current medication list for drug interactions. The American Academy of Sleep Medicine (AASM) clinical practice guideline recommends that clinicians consider cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy reserved for patients who do not respond to or cannot access CBT-I [5]. Dr. Michael Sateia, lead author of the AASM guideline, stated: "Pharmacologic treatment should be individualized based on symptom pattern, treatment goals, past treatment responses, patient preference, cost, availability of other treatments, comorbid conditions, and side effect profiles" [5].

A prescription for Dayvigo is typically written for 5 mg once nightly, taken within 30 minutes of bedtime with at least 7 hours of intended sleep remaining. Your prescriber may increase the dose to 10 mg based on clinical response [1].

Step 2: Choose a Telehealth or In-Person Route

Alabama's telehealth laws allow licensed prescribers to evaluate and prescribe Schedule IV medications via audio-video visits. That is good news for patients in rural counties. According to the Alabama Department of Public Health, an estimated 38.2% of Alabama adults report short sleep duration (defined as fewer than 7 hours per night), the second-highest rate in the United States [6].

For telehealth-based prescribing in Alabama, the provider must:

1. Hold an active Alabama medical license or Alabama telemedicine license
2. Conduct a real-time audio-video evaluation (phone-only visits do not satisfy Schedule IV prescribing requirements)
3. Establish a legitimate provider-patient relationship during the encounter
4. Transmit the prescription electronically to an Alabama-licensed pharmacy via EPCS (Electronic Prescribing for Controlled Substances)

In-person visits at a sleep medicine clinic or primary care office remain the standard option in metro areas such as Birmingham, Huntsville, Mobile, and Montgomery. Many sleep medicine practices in these cities can complete an evaluation and write a prescription in a single visit if no sleep study is indicated.

What Labs or Tests Are Needed Before Starting Dayvigo?

No specific laboratory tests are required before starting lemborexant. The FDA label does not mandate bloodwork prior to prescribing [1]. Your provider may order labs based on your individual clinical picture, not because of drug-specific requirements.

Common evaluations your clinician might perform include a sleep questionnaire (such as the Insomnia Severity Index), a review of the Epworth Sleepiness Scale, screening for depression and anxiety, and a medication reconciliation to identify drug interactions. CYP3A inhibitors such as itraconazole are particularly relevant: the FDA prescribing information contraindicates concomitant use of lemborexant with strong CYP3A inhibitors because of a 4.4-fold increase in lemborexant exposure [1].

If your provider suspects obstructive sleep apnea, a home sleep apnea test or in-lab polysomnography may be ordered before initiating any insomnia medication. This is standard clinical practice, not a Dayvigo-specific requirement.

Navigating Prior Authorization in Alabama

Most commercial insurance plans in Alabama cover Dayvigo but require prior authorization (PA). The PA process exists because insurers want documentation that less expensive alternatives (such as generic zolpidem or suvorexant) were tried or considered first.

Documents your provider will need for a Dayvigo PA submission:

• Diagnosis code (ICD-10 G47.00 for insomnia, unspecified)
• Documentation of failed trials or contraindications to at least one first-line agent (commonly zolpidem or trazodone)
• Clinical notes describing symptom severity and duration (typically 3 months or longer of insomnia symptoms)
• If CBT-I was attempted: dates and outcome summary
• Provider's rationale for selecting lemborexant over formulary alternatives

PA decisions from commercial insurers in Alabama typically take 1 to 5 business days for standard requests. Urgent or expedited reviews can return a decision within 24 to 72 hours. If denied, your provider can file a peer-to-peer appeal, during which they speak directly with the insurer's medical director.

Alabama Medicaid does not currently list Dayvigo on its preferred drug list for insomnia. Patients covered by Alabama Medicaid may need to pursue a non-preferred drug exception, which requires stronger documentation of medical necessity. Success rates for these exceptions vary. An alternative path is the Eisai co-pay assistance program, which may cover out-of-pocket costs for commercially insured patients but does not apply to Medicaid, Medicare, or other federal programs [7].

Pharmacy Options: Retail, Mail Order, and 503A Compounding

Once you have a valid prescription, you can fill Dayvigo at any Alabama-licensed pharmacy. Here is how the main options compare.

Retail pharmacy: Major chains (CVS, Walgreens, Walmart) and independent pharmacies across Alabama stock or can order Dayvigo. Cash price without insurance ranges from approximately $350 to $420 for a 30-day supply. The Eisai savings card can reduce insured co-pays to $0 for eligible patients.

Mail-order pharmacy: If your insurance plan includes a mail-order benefit, you can often get a 90-day supply at a lower per-unit cost. The prescription must still be transmitted via EPCS from an Alabama-licensed prescriber.

503A compounding pharmacies: Alabama-licensed 503A compounding pharmacies may compound lemborexant for individual patients with a valid prescription if a clinical need exists (such as a patient who cannot swallow tablets). Under section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies must compound in response to individual prescriptions and cannot produce bulk quantities for office use [8]. Not all 503A pharmacies in Alabama carry the raw ingredient, so call ahead.

Clinical Evidence Supporting Lemborexant for Insomnia

The efficacy data for lemborexant come primarily from two registration trials. SUNRISE-1 was a randomized, double-blind, placebo- and active-controlled (zolpidem 6.25 mg ER) trial in 1,006 adults aged 55 years and older with insomnia disorder [3]. At one month, lemborexant 5 mg reduced subjective sleep onset latency by a mean of 11.6 minutes more than placebo, and lemborexant 10 mg reduced it by 13.4 minutes more than placebo (both p<0.001).

SUNRISE-2 was a 12-month safety and efficacy study in 949 adults aged 18 years and older [9]. At 6 months, lemborexant 5 mg and 10 mg significantly improved subjective sleep onset latency and wake after sleep onset compared with placebo. Dr. Margaret Moline, then Eisai's vice president of clinical research, noted: "The sustained improvement over six months without evidence of dose escalation or rebound insomnia supports the use of lemborexant for longer-term treatment of insomnia" [9].

A post hoc analysis of both SUNRISE trials found that lemborexant 10 mg was associated with significantly greater improvements in next-day functioning compared with placebo, as measured by the Insomnia Severity Index total score (p<0.001) [10]. No evidence of abuse liability at therapeutic doses was observed across the clinical program, consistent with the drug's Schedule IV classification.

Common adverse effects in the trials included somnolence (lemborexant 10 mg: 10% vs. placebo: 1%), headache (6% vs. 4%), and sleep paralysis (2% vs. 0.5%) [1]. Rates of complex sleep behaviors (such as sleepwalking) were low and comparable across treatment groups.

Cost Breakdown and Savings Programs

The average wholesale acquisition cost (WAC) for Dayvigo is approximately $14 per tablet, translating to roughly $420 for a 30-day supply at the 5 mg or 10 mg dose [7]. Actual out-of-pocket cost depends on insurance coverage, formulary tier, and available discounts.

For commercially insured patients: Eisai's savings card may bring the co-pay to $0 per fill. Eligibility requires commercial insurance that covers Dayvigo. The card cannot be used with Medicare, Medicaid, TRICARE, or any other government-funded program.

For uninsured or cash-pay patients: Eisai's patient assistance program may provide Dayvigo at no cost for patients who meet income and insurance eligibility criteria. The application requires proof of income and a signed prescription from an Alabama-licensed provider.

For Alabama Medicaid patients: Since Dayvigo is not on the Alabama Medicaid preferred drug list, out-of-pocket cost at cash price is a significant barrier. Providers can submit a non-preferred drug request, but many Medicaid patients end up using formulary alternatives such as generic suvorexant or trazodone. The Endocrine Society and AASM both recognize DORAs as a valid pharmacotherapy class for insomnia, which can support the clinical argument in a Medicaid exception request [5].

Timeline: How Long Until You Receive Dayvigo in Alabama?

The total time from initial visit to medication in hand varies depending on your access route.

Fastest scenario (in-stock retail pharmacy, no PA required): 1 to 2 days. Your provider transmits the e-prescription after the visit, the pharmacy fills it, and you pick it up.

Typical scenario (PA required): 3 to 7 days. The provider submits the PA on day one, the insurer reviews it in 1 to 5 business days, and the pharmacy fills the prescription after approval.

Longer scenario (PA denied, appeal filed): 7 to 21 days. A peer-to-peer review or formal appeal adds time. Some patients fill a short bridge supply at cash price while awaiting the appeal outcome.

Telehealth scenario: Add 0 to 1 days for electronic prescription routing. Most telehealth platforms transmit prescriptions within hours of the visit.

If your pharmacy does not have Dayvigo in stock, expect an additional 1 to 2 business days for the wholesaler to deliver the medication. Rural pharmacies in Alabama may need to special-order the drug.

Transferring an Existing Dayvigo Prescription to Alabama

If you already have a Dayvigo prescription from another state and are moving to or visiting Alabama, the process depends on the prescription type. Because lemborexant is a Schedule IV controlled substance, Alabama law permits the transfer of an original prescription between pharmacies one time only under DEA regulations [2]. After that single transfer, you will need a new prescription from an Alabama-licensed provider.

For patients relocating to Alabama permanently, the most reliable approach is to schedule a visit (telehealth or in-person) with a new Alabama provider who can evaluate your insomnia history and write a fresh prescription. Bring your medication records, including the prescribing provider's name, the dose, and the pharmacy where you last filled.